Medical technology company TELA Bio has announced the commercial launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, a product tailored for laparoscopic and robotic-assisted procedures, in the US.
The move is intended to meet the demand for more natural repair options in the more than 665,000 inguinal hernia procedures performed in the country every year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Available in three configurations, OviTex IHR offers flexibility for surgeons based on patient needs and procedural preferences.
Building upon the established OviTex portfolio, the product combines ovine (sheep) rumen with a minimal amount of polymer suture for strength, aiming to reduce the permanent polymer presence.
A retrospective study, ‘Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR)’, highlighted the efficacy of OviTex.
Led by Indiana Hernia Center medical director Dr Paul Szotek, the research assessed OviTex Core Permanent in different hernia repair techniques and indications.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt included the analysis of 259 subjects who underwent robotic inguinal hernia TAPP repair with the help of the ReBAR technique and demonstrated a low recurrence rate of 1.2% with an average follow-up of 1.5 years.
Szotek said: “Since 2018, utilisation of OviTex in inguinal hernia repairs has consistently delivered exceptional clinical value, evidenced by low recurrence rates and an unprecedented level of patient satisfaction.
“The introduction of OviTex IHR signifies a pivotal moment in the advancement of the OviTex technology.”
OviTex IHR is designed for use as a surgical mesh to strengthen and/or repair tissue where weakness occurs.
TELA Bio president and CEO Antony Koblish said: “The inguinal hernia market has historically been dominated by permanent synthetic mesh with few viable alternatives to address the shortcomings of those materials.
“With the introduction of OviTex IHR, we are addressing this need and providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response.”
Last year, Tela Bio introduced its new OviTex PRS Long-Term Resorbable product in the US.
The OviTex PRS is intended for implantation to bolster soft tissue in weak patients who need tissue repair or reinforcement in plastic and reconstructive surgery.
